AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases SKYRIZI to treat moderate to severe plaque psoriasis in adults RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency Synthroid used in the treatment of hypothyroidism AndroGel for males diagnosed with symptomatic low testosterone Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension Ubrelvy to treat migraine with or without aura in adults Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.